Claims
- 1. An amino acid compound of the following formula (I):
- R.sup.1 NH--CH(R.sup.2)--CONH--A--ONO.sub.2 (I)
- wherein R.sup.1 is hydrogen atom, a C.sub.1 -C.sub.5 alkanoyl group, a C.sub.1 -C.sub.4 alkoxycarbonyl group, a benzyloxycarbonyl group, a furylcarbonyl group, a thienylcarbonyl group, a nicotinoyl group or an isonicotinoyl group;
- R.sup.2 is a C.sub.1 -C.sub.4 alkyl group having a substituent, said substituent is a mercapto group, a C.sub.1 -C.sub.5 alkanoylthio group, a C.sub.1 -C.sub.4 alkoxycarbonylthio group, a (5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxycarbonylthio group, a C.sub.6 -C.sub.10 arylcarbonylthio group or a 5- or 6-membered aromatic heterocyclic carbonylthio group containing 1 nitrogen atom, oxygen atom or sulfur atom; and
- A is an ethylene group.
- 2. The compound according to claim 1 wherein R.sup.1 is a hydrogen atom, an acetyl, propionyl, butyryl, isobutyryl or pivaloyl group.
- 3. The compound according to claim 1 wherein R.sup.2 is a mercaptomethyl, acetylthiomethyl, isobutyrylthiomethyl, pivaloylthiomethyl, benzoylthiomethyl or ethoxycarbonylthiomethyl group.
- 4. The compound according to claim 1 wherein R.sup.1 is a hydrogen atom, an acetyl, propionyl, butyryl, isobutyryl or pivaloyl group:
- R.sup.2 is a mercaptomethyl, acetylthiomethyl, isobutyrylthiomethyl, pivaloylthiomethyl, benzoylthiomethyl or ethoxycarbonylthiomethyl group; and
- A is an ethylene group.
- 5. N-(2-Nitrooxyethyl)-2-amino-3-mercaptopropanamide and pharmacologically acceptable salts thereof.
- 6. N-(2-Nitrooxyethyl)-2-acetylamino-3-mercaptopropanamide and pharmacologically acceptable salts thereof.
- 7. N-(2-Nitrooxyethyl)-2-acetylamino-3-acetylthiopropanamide and pharmacologically acceptable salts thereof.
- 8. N-(2-Nitrooxyethyl)-2-acetylamino-3-pivaloylthiopropanamide and pharmacologically acceptable salts thereof.
- 9. N-(2-Nitrooxyethyl)-2-acetylamino-3-ethoxycarbonylthiopropanamide and pharmacologically acceptable salts thereof.
- 10. N-(2-Nitrooxyethyl)-2-acetylamino-3-benzoylthiopropanamide and pharmacologically acceptable salts thereof.
- 11. N-(2-Nitrooxyethyl)-2-isobutyrylamino-3-isobutyrylthiopropanamide and pharmacologically acceptable salts thereof.
- 12. N-(2-Nitrooxyethyl)-2-acetylamino-3-(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxycarbonylthiopropanamide and pharmacologically acceptable salts thereof.
- 13. An angina pectoris therapeutic composition comprising an anti-anginal effective amount of a compound according to claim 1 and a pharmacologically acceptable adjuvant.
- 14. The angina pectoris therapeutic composition according to claim 13 wherein R.sup.1 is a hydrogen atom, an acetyl, propionyl, butyryl, isobutyryl or pivaloyl group.
- 15. The angina pectoris therapeutic composition according to claim 13 wherein R.sup.2 is a mercaptomethyl, acetylthiomethyl, isobutyrylthiomethyl, pivaloylthiomethyl, benzoylthiomethyl or ethoxycarbonylthiomethyl group.
- 16. The angina pectoris therapeutic composition according to claim 13 wherein R.sup.1 is a hydrogen atom, an acetyl, propionyl, butyryl, isobutyryl or pivaloyl group;
- R.sup.2 is a mercaptomethyl, acetylthiomethyl, isobutyrylthiomethyl, pivaloylthiomethyl, benzoylthiomethyl or ethoxycarbonylthiomethyl group.
- 17. The angina pectoris therapeutic composition according to claim 13 wherein the active ingredient is selected from the following compounds:
- N-(2-nitrooxyethyl)-2-amino-3-mercaptopropanamide and pharmacologically acceptable salts thereof;
- N-(2-nitrooxyethyl)-2-acetylamino-3-mercaptopropanamide and pharmacologically acceptable salts thereof;
- N-(2-nitrooxyethyl)-2-acetylamino-3-acetylthiopropanamide and pharmacologically acceptable salts thereof:
- N-(2-nitrooxyethyl)-2-acetylamino-3-pivaloylthiopropanamide and pharmacologically acceptable salts thereof;
- N-(2-nitrooxyethyl)-2-acetylamino-3-ethoxycarbonylthiopropanamide and pharmacologically acceptable salts thereof;
- N-(2-nitrooxyethyl)-2-acetylamino-3-benzoylthiopropanamide and pharmacologically acceptable salts thereof:
- N-(2-nitrooxyethyl)-2-isobutyrylamino-3-isobutyrylthiopropanamide and pharmacologically acceptable salts thereof; and
- N-(2-nitrooxyethyl)-2-acetylamino-3-(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxycarbonylthiopropanamide and pharmacologically acceptable salts thereof.
- 18. A method for treating a patient suffering from angina pectoris comprising administering to the patient an effective anti-anginal amount of the compound of claim 1.
- 19. The method according to claim 18, wherein the compound is selected from the group consisting of
- N-(2-nitrooxyethyl)-2-amino-3-mercaptopropanamide,
- N-(2-nitrooxyethyl)-2-acetylamino-3-mercaptopropanamide,
- N-(2-nitrooxyethyl)-2-acetylamino-3-acetyl-thiopropanamide,
- N-(2-nitrooxyethyl)-2-acetylamino-3-pivaloylthiopropanamide,
- N-(2-nitrooxyethyl)-2-acetylamino-3-ethoxy-carbonylthiopropanamide,
- N-(2-nitrooxyethyl)-2-acetylamino-3-benzoylthiopropanamide,
- N-(2-nitrooxyethyl)-2-isobutyrylamino-3-isobutyrylthiopropanamide,
- N-(2-nitrooxyethyl)-2-acetylamino-3-(5-methyl-2-oxo-1,3-dioxolen-4-yl)methoxycarbonylthiopropanamide and
- pharmacologically acceptable salts thereof.
Priority Claims (1)
Number |
Date |
Country |
Kind |
3-164585 |
Jul 1991 |
JPX |
|
Parent Case Info
This application is a Continuation of application Ser. No. 08/170,174, filed Dec. 17, 1993, now abandoned which is the United States national phase 371 application of International Application No. PCT/JP92/00823 filed Jun. 30, 1992.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5037849 |
Simon et al. |
Aug 1991 |
|
5284872 |
Sandrock et al. |
Feb 1994 |
|
Continuations (1)
|
Number |
Date |
Country |
Parent |
170174 |
Dec 1993 |
|